Assessing Nephrotoxicity Associated With Different Vancomycin Dosing Modalities in Obese Patients at a Community...

Area of Science:

• Pharmacology and Therapeutics
• Nephrology
• Infectious Diseases

Background:

• Vancomycin therapeutic drug monitoring (TDM) guidelines increasingly favor area under the curve over 24 hours (AUC24) over trough concentrations.
• Obesity is a known risk factor for vancomycin-induced nephrotoxicity, linked to altered drug exposure.
• This study investigates the impact of AUC-based versus trough-based vancomycin dosing on nephrotoxicity in obese patients.

Purpose of the Study:

• To compare the incidence of nephrotoxicity between AUC-based and trough-based vancomycin dosing strategies in obese adults.
• To evaluate secondary outcomes including vancomycin loading dose exposure, total daily dose, and achievement of therapeutic drug monitoring targets.

Main Methods:

• Retrospective, observational, single-centered study of obese adults receiving vancomycin for at least 48 hours.
• Data collected from electronic medical records for patients with pharmacokinetic consults using either trough-only or AUC-based dosing.
• Statistical analysis included chi-square tests for nominal data and t-tests or Mann-Whitney tests for continuous data.

Main Results:

• Nephrotoxicity occurred in 6.3% of the AUC cohort versus 17.4% in the trough cohort (P = .035).
• The AUC cohort received a higher median loading dose (20 mg/kg) compared to the trough cohort (16 mg/kg).
• Therapeutic drug monitoring target attainment was significantly higher in the AUC cohort (73.7%) compared to the trough cohort (25.4%) (P < .001).

Conclusions:

• AUC-based vancomycin dosing is associated with a significant reduction in acute kidney injury (AKI) in obese patients.
• Despite higher loading doses, AUC dosing leads to better achievement of therapeutic drug levels and reduced nephrotoxicity.
• This supports the adoption of AUC-based TDM for vancomycin in obese populations to optimize efficacy and safety.